Table 1 Unadjusted and adjusted risk ratios for any malignant cancer and specific cancers among patients with type 2 diabetic people and their comparators in Tayside, Scotland, 1993–2004
From: A cohort study of the risk of cancer associated with type 2 diabetes
No (%) of cancer (diabetes) | No (%) of cancer (comparators) | Unadjusted RR (95% CI) | Adjusted RR (95% CI)a | Adjusted RR (95% CI) (excluding outcomes in 1st year) | |
|---|---|---|---|---|---|
Any malignant cancer C00–97 | 661 (6.9%) | 1364 (7.1%) | 1.01 (0.92–1.11) | 0.99 (0.90–1.09) | 1.05 (0.93–1.18) |
Skin C43–44 | 128 (1.3%) | 322 (1.7%) | 0.83 (0.68–1.02) | 0.84 (0.68–1.03) | 0.83 (0.64–1.07) |
Lung C33–34 | 77 (0.8%) | 198 (1.0%) | 0.81 (0.62–1.05) | 0.77 (0.59–1.01) | 0.70 (0.49–0.99) |
Colon C18–19 | 67 (0.7%) | 95 (0.5%) | 1.49 (1.09–2.03) | 1.46 (1.07–2.01) | 1.56 (1.05–2.32) |
Breast C50 | 52 (0.5%) | 103 (0.5%) | 1.05 (0.76–1.47) | 1.05 (0.75–1.47) | 1.05 (0.71–1.57) |
Prostate C61 | 43 (0.4%) | 117 (0.6%) | 0.77 (0.54–1.09) | 0.77 (0.54–1.09) | 0.76 (0.50–1.17) |
Pancreas C25 | 31 (0.3%) | 20 (0.1%) | 3.19 (1.82–5.60) | 3.06 (1.73–5.39) | 2.85 (1.27–6.43) |
Oesophagus C15 | 24 (0.3%) | 28 (0.1%) | 1.79 (1.04–3.08) | 1.70 (0.98–2.95) | 1.74 (0.91–3.32) |
Bladder C67 | 17 (0.2%) | 51 (0.3%) | 0.69 (0.40–1.20) | 0.70 (0.40–1.21) | 0.53 (0.24–1.15) |
Non-Hodgkins C82–85 | 17 (0.2%) | 26 (0.1%) | 1.37 (0.74–2.51) | 1.36 (0.74–2.51) | 1.44 (0.67–3.10) |
Liver C22 | 17 (0.2%) | 12 (0.1%) | 2.96 (1.41–6.19) | 2.93 (1.40–6.14) | 3.50 (1.38–8.91) |
Stomach C16 | 16 (0.2%) | 46 (0.2%) | 0.73 (0.41–1.29) | 0.73 (0.41–1.29) | 0.77 (0.36–1.66) |
Rectum C20 | 13 (0.1%) | 48 (0.3%) | 0.57 (0.31–1.06) | 0.56 (0.30–1.03) | 0.53 (0.25–1.10) |
Endometrium C54 | 13 (0.1%) | 17 (0.1%) | 1.60 (0.78–3.29) | 1.47 (0.70–3.09) | 0.94 (0.33–2.70) |
Kidney C64 | 6 (0.1%) | 24 (0.1%) | 0.52 (0.21–1.28) | 0.52 (0.21–1.27) | 0.25 (0.06–1.06) |
